

06. Ending TB in India: Why civil society should dream and act big

**THE 46TH UNION
WORLD CONFERENCE
ON LUNG HEALTH**

CAPE TOWN, SOUTH AFRICA
2-6 DECEMBER 2015

Friday, 04 December 2015, 17:30 - 18:45

Room MR 2.41-2.43

Type of session	Sponsored Satellite Symposium
Track	Civil society / patient & community engagement
Track2 (optional)	Advancing the End TB strategy and other policy issues
Organised by	Médecins Sans Frontières Access Campaign
Description	India contributes globally more than a quarter of the world's TB patients and ranks first among 27 MDR-TB high-burden countries. If the targets of the END TB strategy are to be reached, significant improvements are urgently needed. Universal access to new and existing diagnostics is moving slowly; novel treatment modalities for MDR-TB are not being offered; patient-centred approaches have not been defined; and there is a lack of innovation in the R&D agenda despite India's research and funding potential. The Indian civil society needs to be an important catalyst for speeding up the 'End of TB'.
Target audience	<ol style="list-style-type: none"> 1. Treatment activists and organisations 2. HIV and TB community members 3. Civil society organisations
Objectives	<ol style="list-style-type: none"> 1. Identify gaps in the current model of diagnosis, treatment and care in India 2. Facilitate civil society and community engagement in drafting and implementing TB treatment guidelines 3. Facilitate civil society engagement in R&D for TB, including advocacy for clinical and operational research 4. Outline and focus on key policy areas to achieve rapid improvements in TB treatment and care
Keywords	Civil society; diagnostics and treatment; research and development (R&D)
Coordinator(s)	Shailly Gupta (India), Petros Isaakidis (India)
Chair(s)	Jennifer Furin (USA), Grania Brigden (France)
Presentations	<p>17:30 - 17:45 Policies impeding access to diagnosis, treatment and care in the public health programme for TB-HIV co-infected patients Vikas Ahuja (India)</p> <p>17:45 - 18:00 Challenges in TB care delivery in India targeting vulnerable groups Tsetan Dorji Sadutshang (India)</p> <p>18:00 - 18:15 Use of the new TB drugs in India: road ahead Zarir Udhwadia (India)</p> <p>18:15 - 18:30 Access to improved tools and regimens to diagnose and treat all forms of TB and TB-HIV Homa Mansoor (India)</p> <p>18:30 - 18:45 Why does civil society need to be engaged on the TB research agenda (including clinical trials)? Erica Lessem (USA)</p>